Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

HAEMONETICS

Haemonetics Corporation’s comprehensive portfolio of devices, information management, and consulting services offers ... read more Featured Products: More products

Download Mobile App




Hypercoagulability Evaluated in New‐Onset Systemic Lupus Erythematosus Patients

By LabMedica International staff writers
Posted on 30 Dec 2019
Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that involves T cell, B cell, and dendritic cell dysfunction, as well as antinuclear autoantibody production. More...
Several clinical and scientific studies of SLE indicate an increased risk of thrombosis in these cases.

The traditional parameters for screening coagulopathy include prothrombin time (PT) and activated partial thromboplastin time (aPTT). The thromboelastography (TEG) procedure facilitates the functional evaluation of the coagulation cascade, from clot formation to clot lysis, and provides data on the entire coagulation system.

Medical scientists at the Shanghai Jiao Tong University School of Medicine (Shanghai, China) enrolled in a study a total of 41 patients with new‐onset SLE who had not undergone treatment were enrolled, and 56 healthy individuals were included as controls. Blood samples were collected using 18G needles and vacutainer tubes containing ethylenediaminetetraacetic acid (EDTA) (for complete blood cell count) and 3.2% trisodium citrate (for TEG and coagulation analyses). Moreover, 24‐hour urine collection was performed in a clean dry container.

Complete blood counts were obtained using an automated hematology analyzer DXH800 (Beckman Coulter, Brea, CA, USA). The reference range for PLT count was 101‐320 × 109/L. Routine coagulation screening assays, including PT, aPTT, fibrinogen (Fg), thrombin time (TT), d‐dimer (DD), and fibrinogen/fibrin degradation products (FDP), were performed in all the patients using an automated coagulometer CS5100 (Sysmex Corporation, Kobe, Japan). Lupus anticoagulant (LAC) status was examined using ACL‐TOP700 (Instrumentation Laboratory, Bedford, MA, USA). Blood clot formation and stability were evaluated via TEG tests using a thromboelastography analyzer (Haemonetics Corporation, Braintree, MA, USA).

The team reported that there was a significant difference in the TEG reaction time and TEG achievement of clot firmness between the groups. Moreover, these parameters were correlated with the lupus anticoagulant levels, platelet count, 24‐hour urinary total protein quantity, and systemic lupus erythematosus disease activity index ((SLEDAI). The TEG parameters were correlated with other clinical and laboratory data, such as LAC status, PLT level, and urinary total protein (UTP) and SLEDAI values. Patients with positive LAC status, higher PLT levels, UTP >500 mg/24 hours and higher SLEDAI values are known to have a greater risk of thrombosis.

The authors concluded that they have demonstrated the prospective value of TEG in evaluating hypercoagulability in patients with SLE. The study was published on December 16, 2019 in the Journal of Clinical Laboratory Analysis.

Related Links:
Shanghai Jiao Tong University School of Medicine
Beckman Coulter
Sysmex Corporation
Instrumentation Laboratory
Haemonetics Corporation



Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The two new tests are used with the LightCycler 480 and LightCycler PRO instruments (Photo courtesy of Roche)

New PCR Assays Expand Cyclospora Testing for Outbreak Surveillance

Cyclospora cayetanensis, a food- and waterborne intestinal parasite, can cause prolonged diarrhea, fatigue, and abdominal cramping, placing added strain on urgent care and emergency departments during outbreaks.... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.